荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09995 荣昌生物

已收盘 11-18 16:08:08

15.920

-1.220

-7.12%

最高17.320	最低15.900	成交量230.26万
今开17.160	昨收17.140	日振幅8.28%
总市值86.66亿	流通市值30.25亿	总股本5.44亿
成交额3,785万	换手率1.21%	流通股本1.90亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09995","market":"HK","secType":"STK","nameCN":"荣昌生物","latestPrice":15.92,"timestamp":1731917288022,"preClose":17.14,"halted":0,"volume":2302629,"delay":0,"floatShares":190000000,"shares":544332083,"eps":-3.0070684,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.22,"latestTime":"11-18 16:08:08","open":17.16,"high":17.32,"low":15.9,"amount":37850351,"amplitude":0.082847,"askPrice":16,"askSize":4500,"bidPrice":15.92,"bidSize":5500,"shortable":3,"etf":0,"ttmEps":-3.093356174373346,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731979800000},"adr":0,"listingDate":1604851200000,"adjPreClose":17.14,"openAndCloseTimeList":[[1731893400000,1731902400000],[1731906000000,1731916800000]],"volumeRatio":1.084765,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688331","market":"SH","secType":"STK","nameCN":"荣昌生物","latestPrice":31.87,"timestamp":1731913200000,"preClose":33.14,"halted":0,"volume":3373916,"delay":0,"premium":"-53.49"}},"requestUrl":"/m/hq/s/09995/wiki","defaultTab":"wiki","newsList":[{"id":"2484618824","title":"荣昌生物(09995)下跌5.13%，报16.26元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484618824","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484618824?lang=zh_cn&edition=full","pubTime":"2024-11-18 14:10","pubTimestamp":1731910220,"startTime":"0","endTime":"0","summary":"11月18日，荣昌生物(09995)盘中下跌5.13%，截至14:10，报16.26元/股，成交1974.22万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年三季报，荣昌生物营业总收入12.09亿元、净利润-10.71亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/18141045391699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2148510915.USD","09995","LU1064130708.USD","BK1574","688331","BK0239","LU1064131003.USD","BK1583","LU2328871848.SGD","BK1161","LU1969619763.USD"],"gpt_icon":0},{"id":"2484613123","title":"荣昌生物盘中异动 快速下挫5.13%报16.260港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2484613123","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484613123?lang=zh_cn&edition=full","pubTime":"2024-11-18 14:10","pubTimestamp":1731910220,"startTime":"0","endTime":"0","summary":"2024年11月18日下午盘14时10分，荣昌生物股票出现波动，股价快速下挫5.13%。截至发稿，该股报16.260港元/股，成交量117.6万股，换手率0.62%，振幅6.18%。资金方面，该股资金流入545.76万港元，流出1272.74万港元。荣昌生物股票所在的生物技术行业中，整体跌幅为1.35%。其相关个股中，贝康医疗-B、正大企业国际、基石药业-B涨幅较大，振幅较大的相关个股有晶泰科技、正大企业国际、荃信生物-B，振幅分别为16.26%、16.05%、15.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118141020abcb6110&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241118141020abcb6110&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","LU1969619763.USD","09995","BK1161","LU2328871848.SGD","BK1583"],"gpt_icon":0},{"id":"2483363346","title":"荣昌生物公布马兰拟辞任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2483363346","media":"新浪港股","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483363346?lang=zh_cn&edition=full","pubTime":"2024-11-15 08:23","pubTimestamp":1731630180,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　荣昌生物（09995）发布公告，公司董事会近日收到独立非执行董事马兰博士的书面辞呈。马兰博士根据中国科学院院士兼职管理的相关规定，提出辞去董事会独立非执行董事及提名委员会、战略委员会委员职务。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-15/doc-incwaxxs6538029.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-11-15/doc-incwaxxs6538029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","LU2148510915.USD","LU1064131003.USD","BK1583","LU1064130708.USD","688331","BK0239","LU2328871848.SGD","LU1969619763.USD","BK1161","09995"],"gpt_icon":0},{"id":"2483122879","title":"荣昌生物(09995)：马兰拟辞任独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2483122879","media":"智通财经","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483122879?lang=zh_cn&edition=full","pubTime":"2024-11-14 20:15","pubTimestamp":1731586532,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荣昌生物(09995)发布公告，公司董事会近日收到独立非执行董事马兰博士的书面辞呈。马兰博士根据中国科学院院士兼职管理的相关规定，提出辞去董事会独立非执行董事及提名委员会、战略委员会委员职务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1211146.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","LU2328871848.SGD","LU1969619763.USD","BK0239","LU1064131003.USD","LU2148510915.USD","BK1574","09995","688331","LU1064130708.USD"],"gpt_icon":0},{"id":"2483840538","title":"荣昌生物最新公告：独立董事马兰辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2483840538","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483840538?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:52","pubTimestamp":1731574362,"startTime":"0","endTime":"0","summary":"荣昌生物公告称，董事会近日收到独立董事马兰的书面辞职报告。马兰因根据中国科学院院士兼职管理的相关规定，申请辞去公司第二届董事会独立董事及提名委员会、战略委员会委员职务。辞职后，马兰将不再担任公司任何职务。其辞职报告将在新的独立董事到任之日或者独立董事人数不少于公司董事会人数的三分之一起生效。在此之前，马兰仍将按照有关法律法规和《公司章程》的规定继续履行职责。公司将按照相关规定，尽快完成新任独立董事的补选工作。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111400027173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK1583","LU2328871848.SGD","BK0239","BK1574","BK1161","09995","LU1969619763.USD","LU1064130708.USD","688331","LU1064131003.USD"],"gpt_icon":0},{"id":"2483406708","title":"荣昌生物：关于独立董事辞职的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2483406708","media":"新浪财经-鹰眼工作室","labels":["Executive Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483406708?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:40","pubTimestamp":1731573600,"startTime":"0","endTime":"0","summary":"荣昌生物制药（烟台）股份有限公司关于独立董事辞职的公告本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。荣昌生物制药（烟台）股份有限公司董事会近日收到独立董事马兰女士的书面辞职报告。辞职后，马兰女士将不再担任公司任何职务。公司将按照相关规定，尽快完成新任独立董事的补选工作。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/ggzz/2024-11-14/doc-incvzmwk7182463.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-11-14/doc-incvzmwk7182463.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Executive Changes","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09995","LU1064131003.USD","688331","LU1064130708.USD","BK1583","LU2148510915.USD","BK1161","BK0239","BK1574","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2483684277","title":"荣昌生物独立董事马兰辞职","url":"https://stock-news.laohu8.com/highlight/detail?id=2483684277","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483684277?lang=zh_cn&edition=full","pubTime":"2024-11-14 16:32","pubTimestamp":1731573120,"startTime":"0","endTime":"0","summary":"财中社11月14日电荣昌生物（688331/09995）发布关于独立董事辞职的公告。独立董事马兰因根据中国科学院院士兼职管理的相关规定，申请辞去公司第二届董事会独立董事及相关委员会职务。辞职后，马兰将不再担任公司任何职务。由于马兰的辞职将导致公司独立董事人数少于董事会成员的三分之一，其辞职报告将在新的独立董事到任之日或独立董事人数恢复到不少于董事会人数的三分之一时生效。在此之前，马兰将继续履行职责。公司将尽快完成新任独立董事的补选工作。2024年前三季度，荣昌生物实现收入12.09亿元，归母净利润-10.71亿元。（文章来源：财中社）","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114163408a236d226&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114163408a236d226&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","09995","688331","LU2328871848.SGD","BK1161","LU1969619763.USD"],"gpt_icon":0},{"id":"2483016890","title":"荣昌生物(09995)股价下跌8.088%，现价港币$17.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2483016890","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483016890?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:35","pubTimestamp":1731465300,"startTime":"0","endTime":"0","summary":"[下跌股]荣昌生物(09995) 股价在上午10:35比前收市价下跌8.088%，现股价为港币$17.5。至目前为止，今日最高价为$18.94，而最低价为$17.5。总成交量为106.6万股，总成交金额为港币$1.926千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2411131151/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["688331","BK0239","LU1969619763.USD","LU2148510915.USD","BK1161","BK1583","BK1574","LU1064131003.USD","LU1064130708.USD","09995","LU2328871848.SGD"],"gpt_icon":0},{"id":"2483018187","title":"荣昌生物(09995)下跌5.04%，报18.08元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483018187","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483018187?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:11","pubTimestamp":1731463867,"startTime":"0","endTime":"0","summary":"11月13日，荣昌生物(09995)盘中下跌5.04%，截至10:11，报18.08元/股，成交680.39万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年三季报，荣昌生物营业总收入12.09亿元、净利润-10.71亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13101145231191.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2148510915.USD","09995","LU2328871848.SGD","688331","LU1064130708.USD","BK0239","LU1064131003.USD","BK1161","LU1969619763.USD","BK1574","BK1583"],"gpt_icon":0},{"id":"2483013812","title":"荣昌生物盘中异动 股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483013812","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483013812?lang=zh_cn&edition=full","pubTime":"2024-11-13 10:11","pubTimestamp":1731463865,"startTime":"0","endTime":"0","summary":"2024年11月13日早盘10时11分，荣昌生物股票出现异动，股价快速跳水5.04%。截至发稿，该股报18.080港元/股，成交量37万股，换手率0.20%，振幅4.52%。荣昌生物股票所在的生物技术行业中，整体跌幅为1.94%。公司发布2024 年三季报，三季度增长符合预期荣昌生物发布2024 年三季报，公司在报告期内营业收入4.67亿人民币，同比增长57.10%，扣非归母净利润-3.04 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111310110698e423e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024111310110698e423e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09995","BK1583","BK1161","BK1574","LU2328871848.SGD","LU1969619763.USD"],"gpt_icon":0},{"id":"2482273207","title":"【券商聚焦】中信建投维持荣昌生物(09995)“买入”评级 指其三季度增长符合预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2482273207","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482273207?lang=zh_cn&edition=full","pubTime":"2024-11-11 15:30","pubTimestamp":1731310205,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投发研报指，2024三季度，荣昌生物 核心产品销售持续放量，单季度收入4.67亿元，同比增长57.10%，符合预期。同时公司三季度归母净亏损3.04亿元，环比缩窄1.44亿元。公司核心产品泰它西普与维迪西妥单抗覆盖自免与肿瘤领域，两款产品的临床研发与商业化推进均在稳步推进状态。但由于公司受到行业变化的影响，该行预计2024-2026年，公司收入分别为15.50亿元、24.53亿元、31.73亿元，维持“买入”评级。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947481","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09995","688331"],"gpt_icon":0},{"id":"1159564570","title":"异动解读 | 荣昌生物三季度业绩符合预期 股价大涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1159564570","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159564570?lang=zh_cn&edition=full","pubTime":"2024-11-11 13:34","pubTimestamp":1731303268,"startTime":"0","endTime":"0","summary":"2024年11月11日,荣昌生物股票在港交所盘中出现大涨行情,股价一度大涨5.26%,引起市场广泛关注。据相关利好消息披露,荣昌生物发布2024年第三季度业绩数据,营业收入同比增长57.1%,达到4.67亿元人民币,表现符合市场预期。分析人士认为,此次公司业绩增长出色,推动市场重新认识公司的产品力和发展前景,从而引发股价大涨。总体来看,随着核心产品市场份额不断扩大,以及丰富的创新药物管线持续推进,公司长期发展动能强劲,投资价值备受看好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"gpt_icon":0},{"id":"2482226368","title":"荣昌生物(09995)上涨5.48%，报19.64元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2482226368","media":"金融界","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482226368?lang=zh_cn&edition=full","pubTime":"2024-11-11 13:15","pubTimestamp":1731302117,"startTime":"0","endTime":"0","summary":"11月11日，荣昌生物(09995)盘中上涨5.48%，截至13:15，报19.64元/股，成交2270.25万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年三季报，荣昌生物营业总收入12.09亿元、净利润-10.71亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/11131545138469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1583","LU2328871848.SGD","LU1064131003.USD","BK1574","688331","BK0239","LU1064130708.USD","09995","BK1161","LU1969619763.USD","LU2148510915.USD"],"gpt_icon":0},{"id":"2482225205","title":"荣昌生物盘中异动 下午盘大幅拉升5.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2482225205","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482225205?lang=zh_cn&edition=full","pubTime":"2024-11-11 13:15","pubTimestamp":1731302114,"startTime":"0","endTime":"0","summary":"2024年11月11日下午盘13时15分，荣昌生物股票出现波动，股价大幅上涨5.48%。截至发稿，该股报19.640港元/股，成交量121.95万股，换手率0.64%，振幅8.92%。荣昌生物股票所在的生物技术行业中，整体跌幅为0.16%。公司发布2024 年三季报，三季度增长符合预期荣昌生物发布2024 年三季报，公司在报告期内营业收入4.67亿人民币，同比增长57.10%，扣非归母净利润-3.04 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111131515971a598a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241111131515971a598a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","09995","BK1161","LU2328871848.SGD","BK1574","BK1583"],"gpt_icon":0},{"id":"2482849291","title":"荣昌生物(9995.HK)：三季度增长符合预期 创新管线持续推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2482849291","media":"中信建投证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482849291?lang=zh_cn&edition=full","pubTime":"2024-11-09 00:00","pubTimestamp":1731081600,"startTime":"0","endTime":"0","summary":"核心观点2024 三季度，公司核心产品销售持续放量，单季度收入4.67亿元，同比增长57.10%，符合预期。同时公司三季度归母净亏损3.04 亿元，环比缩窄1.44 亿元。公司RC18、RC88 多项临床试验成果公布，适应症拓宽、管线丰富未来可期。事件公司发布2024 年三季报，三季度增长符合预期荣昌生物发布2024 年三季报，公司在报告期内营业收入4.67亿人民币，同比增长57.10%，扣非归母净利润-3.04 亿元。公司已有两款核心产品纳入医保目录，销售有望实现持续放量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411091241189f593e96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202411091241189f593e96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09995","LU2328871848.SGD","BK1161","LU1969619763.USD","BK1574","BK1583"],"gpt_icon":0},{"id":"1167553814","title":"异动解读 | 荣昌生物新药进展助推股价大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1167553814","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167553814?lang=zh_cn&edition=full","pubTime":"2024-11-08 21:03","pubTimestamp":1731070990,"startTime":"0","endTime":"0","summary":"11月8日,荣昌生物盘中股价大涨5.09%,引发了市场的广泛关注。公司股价大涨的主要原因是其旗舰产品泰它西普针对IgA肾病适应症取得重大进展。\n\n据公司公告,泰它西普用于IgA肾病适应症的III期临床试验已完成患者入组,目前正处于用药随访阶段。这是泰它西普获批上市在即的重要一步。泰它西普一旦获批上市用于IgA肾病,将显著扩大公司产品的使用范围,为公司带来新的利润增长点。\n\n分析人士指出,投资者对于泰它西普获批上市用于新适应症的预期升温,成为推动荣昌生物股价大涨的主要驱动力。展望未来,随着泰它西普新适应症审批进程的推进,荣昌生物股价有望持续受到资金青睐。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 荣昌生物新药进展助推股价大涨5%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"gpt_icon":0},{"id":"2481172756","title":"荣昌生物：泰它西普用于IgA肾病的Ⅲ期临床入组已完成，目前正在用药随访中","url":"https://stock-news.laohu8.com/highlight/detail?id=2481172756","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481172756?lang=zh_cn&edition=full","pubTime":"2024-11-08 20:51","pubTimestamp":1731070301,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：据报导:泰它西普用于IgA肾病的Ⅲ期临床入组已完成,该研究用药方案分为A阶段和B阶段，A阶段是为了验证泰它西普缓解患者蛋白尿方面的有效性以及安全性，B阶段则验证泰它西普给患者带来的长期肾脏受益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202411083234300126.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202411083234300126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","LU1969619763.USD","BK1574","09995","BK1161","LU2328871848.SGD"],"gpt_icon":0},{"id":"2481599162","title":"荣昌生物(09995)上涨5.09%，报19.42元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2481599162","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481599162?lang=zh_cn&edition=full","pubTime":"2024-11-08 10:33","pubTimestamp":1731033186,"startTime":"0","endTime":"0","summary":"11月8日，荣昌生物(09995)盘中上涨5.09%，截至10:33，报19.42元/股，成交1579.29万元。荣昌生物制药(烟台)股份有限公司的主营业务是发现、开发、生产和商业化同类首创、同类最佳的生物药物，主要针对自身免疫、肿瘤、眼科等重大疾病领域。公司在中国和美国设有实验研究机构和办事处，已创制出一批具有重大临床价值的生物新药。截至2024年三季报，荣昌生物营业总收入12.09亿元、净利润-10.71亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/08103345068274.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU1064131003.USD","LU1969619763.USD","LU2328871848.SGD","BK1583","LU2148510915.USD","688331","BK0239","LU1064130708.USD","BK1161","09995","BK1574"],"gpt_icon":0},{"id":"2481994090","title":"医药股普遍下行 金斯瑞生物科技(01548)跌超3% 第十批国采药品目录官宣 机构料续淘汰力度将加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2481994090","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481994090?lang=zh_cn&edition=full","pubTime":"2024-11-07 09:54","pubTimestamp":1730944476,"startTime":"0","endTime":"0","summary":"金吾财讯 | 医药股普遍下行，荣昌生物 跌4.09%，药明巨诺、金斯瑞生物科技跌超3%，基石药业、百济神州跌逾2%，和黄医药跌1.55%，先声药业跌1.47%，康方生物跌1.19%，云顶新耀跌1.08%。2024年国家医保药品目录调整现场谈判已结束，新目录预计11月底公布，明年1月1日正式实施，涉及127家企业162种药品。此次国采品种数量和入围门槛均为历史之最，预计后续淘汰力度将加大，注射剂比例创新高，将改变相关药企的竞争格局。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947254","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01548","IE00B5MMRT66.SGD","BK1515","LU0348783233.USD","BK1574","LU1794554557.SGD","BK1588","00013","IE00BPRC5H50.USD","HK0000306685.HKD","02096","HK0000320223.HKD","HK0000306701.USD","HK0000320264.USD","LU0417516571.SGD","06160","BK1161","09926","02616","BK1583","01952","BK1576","09939","BK1500","BK1587","IE00B543WZ88.USD","BK1191","159938","LU0348784397.USD","BK1141","LU1969619763.USD","09995","LU0307460666.USD","LU2328871848.SGD","LU0588546209.SGD","02126","LU2488822045.USD","LU1720050803.USD"],"gpt_icon":0},{"id":"1171246046","title":"异动解读 | 荣昌生物股价大跌5.91% 交易活跃但无确切利空消息","url":"https://stock-news.laohu8.com/highlight/detail?id=1171246046","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1171246046?lang=zh_cn&edition=full","pubTime":"2024-11-07 09:53","pubTimestamp":1730944418,"startTime":"0","endTime":"0","summary":"今日早盘,荣昌生物股价出现大幅下跌,盘中一度下跌5.91%至18.07港元。该股成交活跃,成交金额超2亿港元,但并无重大利空消息曝光。从最新财报数据来看,荣昌生物最近一期每股收益为-2.21港元,净利润也出现了亏损,但公司业务依然稳步发展。分析指出,荣昌生物作为生物技术类公司,股票波动较大、资金博弈明显是正常现象。今日的股价下跌或只是个别资金获利离场,或市场观望情绪使然,并无任何确切的利空因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 荣昌生物股价大跌5.91% 交易活跃但无确切利空消息","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["09995"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0795},{"period":"1month","weight":0.1427},{"period":"3month","weight":0.1837},{"period":"6month","weight":-0.4471},{"period":"1year","weight":-0.5914},{"period":"ytd","weight":-0.5423}],"compareEarnings":[{"period":"1week","weight":-0.0628},{"period":"1month","weight":-0.0424},{"period":"3month","weight":0.1145},{"period":"6month","weight":-0.0065},{"period":"1year","weight":0.0894},{"period":"ytd","weight":0.1395}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"荣昌生物制药（烟台）股份有限公司是一家主要从事创新型生物药研发和制造的中国公司。该公司专注于抗体药物偶联物（ADC）、抗体融合蛋白、单克隆抗体及双特异性抗体等治疗性抗体药物的发现、开发与商业化。该公司的主要产品包括泰它西普（RC18）、维迪西妥单抗（RC48）和双靶点融合蛋白（RC28）。该公司的产品主要应用于治疗自身免疫疾病、肿瘤和眼科等重大疾病。该公司主要在国内市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.188174},{"month":2,"riseRate":0.75,"avgChangeRate":0.173193},{"month":3,"riseRate":0.25,"avgChangeRate":-0.108046},{"month":4,"riseRate":0.75,"avgChangeRate":-0.020996},{"month":5,"riseRate":0.25,"avgChangeRate":-0.095931},{"month":6,"riseRate":0.75,"avgChangeRate":0.127279},{"month":7,"riseRate":0.5,"avgChangeRate":-0.067258},{"month":8,"riseRate":0.25,"avgChangeRate":-0.07116},{"month":9,"riseRate":0.5,"avgChangeRate":0.075505},{"month":10,"riseRate":0.5,"avgChangeRate":0.092826},{"month":11,"riseRate":1,"avgChangeRate":0.031036},{"month":12,"riseRate":0.5,"avgChangeRate":0.023444}],"exchange":"SEHK","name":"荣昌生物","nameEN":"REMEGEN"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荣昌生物,09995,荣昌生物股票,荣昌生物股票老虎,荣昌生物股票老虎国际,荣昌生物行情,荣昌生物股票行情,荣昌生物股价,荣昌生物股市,荣昌生物股票价格,荣昌生物股票交易,荣昌生物股票购买,荣昌生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荣昌生物(09995)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荣昌生物(09995)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}